ras homolog family member HGenealiases: ARHH · IMD129 · TTF
Q-omics provides the consensus-scored RHOH profile across patient tissues and cancer cell-line models. RHOH expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RHOH is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RHOH RNA expression shows 21,050 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where RHOH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHOH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHOH survival associations across molecular data types. RHOH RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHOH RNA expression–survival associations across cancer types. High RHOH expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, SKCM, LUAD and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RHOH RNA expression.
This table summarizes RHOH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RHOH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHOH shows lower tumor expression in LUSC, BLCA and COAD and higher tumor expression in KIRC, BRCA and HNSC. The KIRC box plot shows higher RHOH RNA expression in tumor versus normal tissue (log2 FC = +1.472, t-test p < 0.001).
This table shows molecular features associated with RHOH in patient tissues and cancer cell lines. In patient samples, RHOH shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RHOH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
